02500.HK
Venus Medtech (Hangzhou) Inc.
HKSE · Healthcare · Medical - Devices · CN
HKD 1.22
+3.83%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 682.5M | 306.8M | 470.8M | 491.4M | 406.5M |
| Cost of Revenue | 223.0M | 95.0M | 103.1M | 102.2M | 92.5M |
| Gross Profit | 459.5M | 211.8M | 367.7M | 389.2M | 314.0M |
| Operating Expenses | |||||
| R&D Expense | 524.7M | 267.4M | 341.2M | 524.9M | 527.5M |
| SG&A Expense | 610.6M | 292.2M | 391.1M | 454.3M | 452.6M |
| General & Admin Expense | 166.2M | 96.8M | 146.0M | 153.8M | 192.2M |
| Selling & Marketing Expense | 309.6M | 195.5M | 245.1M | 300.5M | 260.4M |
| Other Expenses | (17.9M) | (2.5M) | (17.9M) | (1.4M) | (31.1M) |
| Total Operating Expenses | 1.1B | 557.1M | 714.3M | 977.7M | 948.9M |
| Cost and Expenses | 1.3B | 652.1M | 817.4M | 1.1B | 1.0B |
| Operating Income (EBIT) | (657.8M) | (345.3M) | (346.6M) | (590.0M) | (650.2M) |
| Non-Operating | |||||
| Interest Income | 10.3M | 5.0M | 10.3M | 34.5M | 34.6M |
| Interest Expense | 34.3M | 17.8M | 16.6M | 62.7M | 44.6M |
| Net Interest Income | (23.3M) | (12.8M) | (6.3M) | (28.3M) | (10.0M) |
| Other Non-Op Income/Expense | (469.1M) | (59.6M) | (394.1M) | (146.8M) | (506.1M) |
| Non-Operating Income (excl Interest) | — | — | 377.5M | 101.5M | 22.0M |
| EBT (Pre-Tax Income) | (1.1B) | (404.9M) | (740.7M) | (735.3M) | (1.2B) |
| Income Tax Expense | (21.0M) | 2.8M | (23.3M) | (6.3M) | (34.3M) |
| Bottom Line | |||||
| Net Income | (1.1B) | (407.7M) | (714.3M) | (703.8M) | (1.1B) |
| Earnings from Cont. Ops | (1.1B) | (407.7M) | (717.4M) | (729.1M) | (1.1B) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (1.1B) | (407.7M) | (714.3M) | (703.8M) | (1.1B) |
| Per Share | |||||
| Basic EPS | (HK$2.53) | (HK$0.93) | (HK$1.63) | (HK$1.61) | (HK$2.42) |
| Diluted EPS | (HK$2.53) | (HK$0.93) | (HK$1.63) | (HK$1.61) | (HK$2.42) |
| Revenue Per Share | HK$1.56 | HK$0.70 | HK$1.08 | HK$1.12 | HK$0.93 |
| Shares | |||||
| Basic Shares Outstanding | 437.9M | 437.9M | 437.9M | 437.9M | 437.9M |
| Diluted Shares Outstanding | 437.9M | 437.9M | 437.9M | 437.9M | 437.9M |
| Profitability Metrics | |||||
| EBITDA | (810.3M) | (315.4M) | (613.0M) | (547.8M) | (999.4M) |
| D&A | 224.9M | 29.9M | 111.1M | 124.8M | 112.4M |
| EBIT | (1.0B) | (345.3M) | (724.1M) | (672.6M) | (1.1B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026